ASRS 2023: Insights on AVD-104, a sialic-acid coated nanoparticle therapeutic for geographic atrophy
August 15th 2023Carl Regillo, MD, FACS, FASRS, spoke with our team following the annual ASRS meeting in Seattle, Washington to share insights from his presentation titled, "Modulation of Macrophages and Complement Dysfunction in Non-exudative AMD utilizing novel, sialic-acid coated nanoparticles." Aviceda Therapeutics is unlocking the proteogenomic code of AMD to target proteins and pathways linked to macular degeneration.
ASRS 2023: The Starlight study
August 6th 2023Michael Singer, MD, spoke with our team about the Starlight Study, an optogenetic study looking at patients who had Stargardt's disease at the 2023 ASRS annual meeting. At the meeting, Nanoscope Therapeutics Inc presented key results from its STARLIGHT Phase 2 clinical trial.
ASRS Live: 27-Gauge vs 25-gauge vitrectomy for symptomatic vitreous opacities
July 31st 2023Our team spoke with Shawn Kavoussi, MD, at the 2023 ASRS meeting in Seattle, Washington about his research on using infrared video for vitreous opacities and comparing postoperative reduction in vitreous opacity scores using infrared video with the Heidelberg spectralis unit.
ASRS 2023: 'MacGyver-Inspired' endolaser option for chandelier-assisted scleral buckles
July 31st 2023Richard B Rosen, MD, who is presenting New 'MacGyver-Inspired' Endolaser Option for Chandelier-Assisted Scleral Buckles at the 2023 ASRS meeting in Seattle, Washington spoke with our team about this research.
Current status of corneal crosslinking, emerging treatment options
May 18th 2023In a presentation at the American Society of Cataract and Refractive Surgery meeting in San Diego, Kenneth A. Beckman, MD, FACS, discussed the current status of corneal crosslinking with some emerging treatments, including epi-on crosslinking.
Aflibercept 8 mg for diabetic macular edema: 48-week results from the Phase 2/3 PHOTON trial
May 17th 2023Diana V. Do, MD, presented details of the PHOTON study at the Association for Research in Vision and Ophthalmology annual meeting, held recently in New Orleans, highlighting the safety and efficacy of 8 milligrams of aflibercept.